title: [The efficacy of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of acute leukemia in children].
abstract: Growth factors (G-CSF Neupogen Roche i GM-CSF Leucomax Sandoz) have been applied in 133 therapeutic and prophylactic cycles in 88 children with acute leukaemias. GM-CSF and G-CSF were administered subcutaneously or intravenously at a dose of 2 to 8 micrograms/kg for 2 to 28 days. 45 prophylactic cycles had been administered in children with acute lymphoblastic leukaemia in high risk group and in relapses, which caused significant reduction in the number of infections, time of neutropenia and fever. Therapeutic cytokines cycles were applied when the absolute neutrophil count have fallen below 0.5 x 109/l. We observed significant reduction in duration of neutropenia in these cycles. Tolerance of GM-CSF and G-CSF was good. Side effects were not observed.
authors.affiliation: Katedry i Kliniki Pediatrii, Hematologii i Onkologii Akademii Medycznej w Warszawie.
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: K
authors.initials: K
authors.lastname: Pawelec
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: B
authors.initials: B
authors.lastname: Rosińska
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: H
authors.initials: H
authors.lastname: Bubała
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: D
authors.initials: D
authors.lastname: Boruczkowski
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: A
authors.initials: A
authors.lastname: Kurylak
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007239:Infections / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D009503:Neutropenia / Q000150:complications*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor